Philippe JEAN-PIERRE

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 08/12/2022
• Auteurs : Véronique SuissaSerge GuérinPhilippe Denormandie
• Organismes : Agence des Médecines Complémentaires Adaptées (A-MCA) Le Journal de l'Hypnose et de la santé intégrative (DUNOD) ESG Research Lab Institut du Bien Vieillir [Paris]

---

Résumé : La prévention a été élevée au rang de priorité gouvernementale, jusque dans l’intitulé du nouveau ministère de la Santé et de la prévention. Les débats initiés autour des questions de santé, de culture de la prévention et de complémentarité entre les soins ont pris une place encore plus importante depuis la crise de la covid. C’est dans ce cadre que l’A-MCA a souhaité porter les premières rencontres de la prévention. Dans un moment où les Français recherchent une meilleure qualité de vie, l’enjeu est de pouvoir réfléchir collectivement aux leviers permettant d’introduire une véritable culture de la prévention en santé, de pouvoir s’intéresser à la prévention de manière transverse en abordant différents contextes (écoles, entreprise, habitat) et différents publics (jeunes, adultes, personnes âgées). Au programme : Une diversité d'intervenants (médecins, chercheurs, haut-dirigeants, soignants, praticiens...) pour évoquer de façon transverse la prévention à tous les âges de la vie (bien grandir, bien vivre, bien vieillir). Modérée Par Véronique Suissa, Serge Guérin et sous le Haut Patronage de Madame la Députée Anie VIDAL Intervenants : Dr Alain Ducardonet, Dr Adrian Chaboche, Benoit Péricart, Pascal Brunelet, Pr Jean-Pierre Klein, Mario Bastone, etc.

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 07/12/2022
• Auteurs : Jean SeegersOlivier DupirePhilippe DimonVincent BelletNicole BossisEmmanuel MorinPierre Lemeunier
• Organismes : Institut de l'élevage

---

Résumé : Autonomie en paille et poids économique des achats de litières dans les exploitations d'élevage : analyse rétrospective des données INOSYS Réseaux d'élevage 2001-2020

---

Fichiers liés : 3R_2022_396264_Seegers_J_v2_deposee_sans_numeros_de_lignes.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 06/12/2022
• Auteurs : Andy KarabajakianThibaut GarrivierCarole CrozesNicolas GadotJean-Yves BlayFrédéric BérardPhilippe CérusePhilippe ZrounbaPierre SaintignyCharles MastierJérôme Fayette
• Organismes : Hospices Civils de Lyon Immunité de l’épiderme & allergie - Epidermal Immunity and Allergy [CIRI]
• Publié dans Oncotarget le 22/10/2020

---

Résumé : Abstract Introduction/Background Manifestations of psoriasis in special areas are difficult to treat and are associated with a high disease burden and significant quality of life (QoL) impairment. Topical therapies may be inadequate for these patients, necessitating systemic treatment. Objective The objective of EMBRACE was to evaluate the impact on QoL, efficacy and safety of apremilast 30 mg BID in patients with limited skin involvement with plaque psoriasis manifestations in special areas and impaired QoL. Methods EMBRACE (NCT03774875) was a phase 4, randomized, placebo‐controlled, multinational study. Patients had plaque psoriasis not controlled by topical therapy; lack of response, contraindication or intolerance to conventional first‐line systemic therapy; psoriasis in ≥1 special area (including visible locations, scalp, nails, genital areas or palmoplantar areas); Psoriasis Area and Severity Index (PASI) ≥3 to ≤10; and Dermatology Life Quality Index (DLQI) >10. The primary endpoint was DLQI response (≥4‐point reduction) at Week 16. Results Of 277 randomized patients (apremilast: n = 185; placebo: n = 92), 221 completed Week 16 (apremilast: n = 152; placebo: n = 69). The primary endpoint (≥4‐point reduction in DLQI at Week 16) was met by significantly more patients receiving apremilast (73.3%) versus placebo (41.3%; p < 0.0001). Significantly greater improvement in affected body surface area (BSA) and PASI was observed with apremilast versus placebo at Week 16. There were also significantly greater improvements with apremilast versus placebo in itch numeric rating scale (−2.5 vs. −0.9, p < 0.0001) and skin discomfort/pain visual analog scale (−21.5 vs. −5.4, p = 0.0003) and greater achievement of Patient Benefit Index ≥1 (77% vs. 40%, p < 0.0001) at Week 16. No new safety signals were observed. Conclusions Apremilast significantly improved skin‐related QoL in patients with limited skin involvement with plaque psoriasis in special areas and highly impaired QoL. The safety profile was consistent with prior apremilast studies.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 05/12/2022
• Auteurs : Marie LabatJ P Couperus CabadağAmin GhaithArie IrmanAnthony BerliouxPhilippe BerteaudFrédéric BlacheStefan BockFrançois BouvetFabien BriquezYen-Yu ChangSébastien CordeAlexander DebusCarlos de OliveiraJean-Pierre DuvalYannick DietrichMoussa El AjjouriChristoph EisenmannJulien GautierRené GebhardtSimon GramsUwe HelbigChristian HerbeauxNicolas HubertCharles KitegiOlena KononenkoMichael KuntzschMaxwell LabergeStéphane LêBruno LeluanAlexandre LoulergueVictor MalkaFabrice MarteauManh Huy N. GuyenDriss Oumbarek-EspinosRichard PauschDamien PereiraThomas PüschelJean-Paul RicaudPatrick RommeluereEléonore RousselPascal RousseauSusanne SchöbelMourad SebdaouiKlaus SteinigerKeihan TavakoliCedric ThauryPatrick UferMathieu ValléauMarc VandenbergheJosé VétéranUlrich SchrammMarie-Emmanuelle Couprie
• Organismes : Synchrotron SOLEIL Helmholtz-Zentrum Dresden-Rossendorf Synchrotron SOLEIL Helmholtz-Zentrum Dresden-Rossendorf Helmholtz-Zentrum Dresden-Rossendorf Synchrotron SOLEIL Synchrotron SOLEIL Synchrotron SOLEIL Helmholtz-Zentrum Dresden-Rossendorf Synchrotron SOLEIL Synchrotron SOLEIL Helmholtz-Zentrum Dresden-Rossendorf Laboratoire d'Optique Appliquée Helmholtz-Zentrum Dresden-Rossendorf Synchrotron SOLEIL Synchrotron SOLEIL Synchrotron SOLEIL Synchrotron SOLEIL Helmholtz-Zentrum Dresden-Rossendorf Laboratoire d'Optique Appliquée Helmholtz-Zentrum Dresden-Rossendorf Helmholtz-Zentrum Dresden-Rossendorf Helmholtz-Zentrum Dresden-Rossendorf Synchrotron SOLEIL Synchrotron SOLEIL Synchrotron SOLEIL Laboratoire d'Optique Appliquée Helmholtz-Zentrum Dresden-Rossendorf Helmholtz-Zentrum Dresden-Rossendorf University of Texas at Austin [Austin] Synchrotron SOLEIL Synchrotron SOLEIL Synchrotron SOLEIL Laboratoire d'Optique Appliquée Synchrotron SOLEIL Synchrotron SOLEIL Synchrotron SOLEIL Helmholtz-Zentrum Dresden-Rossendorf Synchrotron SOLEIL Helmholtz-Zentrum Dresden-Rossendorf Synchrotron SOLEIL Synchrotron SOLEIL Laboratoire de Physique des Lasers, Atomes et Molécules - UMR 8523 Laboratoire d'Optique Appliquée Helmholtz-Zentrum Dresden-Rossendorf Synchrotron SOLEIL Helmholtz-Zentrum Dresden-Rossendorf Synchrotron SOLEIL Laboratoire d'Optique Appliquée Helmholtz-Zentrum Dresden-Rossendorf Synchrotron SOLEIL Synchrotron SOLEIL Synchrotron SOLEIL Helmholtz-Zentrum Dresden-Rossendorf Synchrotron SOLEIL
• Publié dans Nature Photonics le 01/11/2020

---

Résumé : Abstract Free-electron lasers generate high-brilliance coherent radiation at wavelengths spanning from the infrared to the X-ray domains. The recent development of short-wavelength seeded free-electron lasers now allows for unprecedented levels of control on longitudinal coherence, opening new scientific avenues such as ultra-fast dynamics on complex systems and X-ray nonlinear optics. Although those devices rely on state-of-the-art large-scale accelerators, advancements on laser-plasma accelerators, which harness gigavolt-per-centimetre accelerating fields, showcase a promising technology as compact drivers for free-electron lasers. Using such footprint-reduced accelerators, exponential amplification of a shot-noise type of radiation in a self-amplified spontaneous emission configuration was recently achieved. However, employing this compact approach for the delivery of temporally coherent pulses in a controlled manner has remained a major challenge. Here we present the experimental demonstration of a laser-plasma accelerator-driven free-electron laser in a seeded configuration, where control over the radiation wavelength is accomplished. Furthermore, the appearance of interference fringes, resulting from the interaction between the phase-locked emitted radiation and the seed, confirms longitudinal coherence. Building on our scientific achievements, we anticipate a navigable pathway to extreme-ultraviolet wavelengths, paving the way towards smaller-scale free-electron lasers, unique tools for a multitude of applications in industry, laboratories and universities.

---

Fichiers liés : Seeded_free-electron_laser_driven_by_a_compact_las.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 01/12/2022
• Auteurs : Philippe Ragel
• Organismes : Patrimoine, Littérature, Histoire

---

Résumé : Ce texte propose de revenir sur les quatre adaptations cinématographiques du roman de James M. Cain "Le facteur sonne toujours deux fois" ("The Postman Always Rings Twice", 1934), et plus particulièrement sur la figure de son héroïne Cora. De Pierre Chenal en 1939 à Tay Garnett en 1946, de Luchino Visconti en 1943 à Bob Rafelson en 1981, il s’agit de dessiner ici les traits du multiple visage de "ténébreuse" qu'y incarne Cora, personnage plus complexe qu’il n’y paraît et où joue pour beaucoup le contexte historique de production qui, à chacune des époques considérées, l’a engendré.

---

Fichiers liés : Philippe Ragel. PLH. Cora à l’épreuve de l’écran..pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 01/12/2022
• Auteurs : Philippe FosseJean-Baptiste FourvelNicolas FrerebeauCarole FritzMietje GermonpréStéphane MadelaineGilles ToselloJean-Philip Brugal
• Organismes : Laboratoire méditerranéen de préhistoire Europe-Afrique Laboratoire méditerranéen de préhistoire Europe-Afrique Archéosciences Bordeaux Laboratoire d'Archéologie Moléculaire et Structurale Centre de recherche et d’études de l’art préhistorique Centre de recherche et d’études de l’art préhistorique Laboratoire méditerranéen de préhistoire Europe-Afrique

---

Résumé : Los lobos (Canis lupus) aparecieron en Europa a finales de la primera mitad del Pleistoceno medio. Estos depredadores eran carnívoros resistentes y jerarquizados que competían con otras especies sociales que compartían una dieta similar: las hienas manchadas fósiles (Crocuta ssp.) y los humanos (Homo ssp.). El impacto del lobo en la formación/modificación de los conjuntos óseos del Pleistoceno es todavía difícil de caracterizar. En el sur de Francia, la especie es común a partir del MIS 8-7 y algunos yacimientos, principalmente kársticos, permiten abordar su paleoecología. Basándose en datos eco-etológicos y neotafonómicos, pero también en yacimientos pleistocenos recientemente estudiados, esta contribución propone una reflexión sobre los criterios que permiten describir a los lobos como ocupantes de cavidades (co-ocurrencia con otras especies identificadas, NISP y NMI de carnívoros y ungulados, consumo de huesos), en comparación con las principales especies osteófagas. Además, se elabora un inventario de las modificaciones antropogénicas, tanto dietéticas (marcas de corte) como simbólicas (arte parietal, arte mueble, ornamentos). Este estudio destaca que los lobos ocupan principalmente cuevas poco profundas, acumulando (?) o carroñeando huesos de ungulados de tamaño medio (cérvidos, cápridos). El consumo se centra en las extremidades de los huesos cortos (costillas, apófisis vertebrales) y en los huesos largos (epífisis) asociados a la presencia de huesos (moderadamente) digeridos.

---

Fichiers liés : FOSSE_ET_AL_2024_LUPUS.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/12/2022
• Auteurs : Michel AziziFelix MahfoudMichael A WeberAndrew S P SharpRoland E SchmiederPhilipp LurzMelvin D LoboNaomi D L FisherJoost DaemenMichael J BlochJan BasileKintur SanghviManish SaxenaPhilippe GosseJ. Stephen JenkinsTerry LevyAlexandre PersuBenjamin KablyLisa ClaudeHelen Reeve-StofferCandace McclureAjay J KirtaneChristopher MullinLisa ThackerayGlenn ChertowThomas KahanHarold DauermanSteven UlleryJ. Dawn AbbottAndreas LoeningRon ZagoriaJohn CostelloCourtney KrathanLuot LewisAndrew McelvarrJohn ReillyMichael CashShannon WilliamsMaria JarvisPete FongCheryl LafferJames GainerMark RobbinsSherron CrookSarita MaddelDavid HsiScott MartinEdward PortnayMaryanne DuceySuzanne RoseElizabeth DelmastroSripal BangaloreStephen WilliamsStanley CabosCarolina Rodriguez AlvarezThomas TodoranEric PowersEmily HodskinsVijay PaladuguAnna TecklenburgChandan DevireddyJanice LeaBryan WellsAmanda FiebachClaudia MerlinFlorian RaderSuhail DohadHyun-Min KimMohammad RashidJosephine AbrahamTheophilus OwanAnu AbrahamIran LavasaniHailey NeilsonDavid CalhounThomas McelderryWilliam MaddoxSuzanne OparilSheila KinderJai RadhakrishnanCandido BatresSuzanne EdwardsJoseph GarasicDoug DrachmanRandy ZusmanKenneth RosenfieldDanny DoMatheen KhuddusSuzanne ZentkoJames O'MearaIlie BarbAbby FosterAlice BoyetteYale WangDesmond JayNedaa SkeikRobert SchwartzRose PetersonJo Anne GoldmanJessie GoldmanGary LedleyNancy KatofSrinivasa PotluriScott BiedermannJacquelyn WardMegan WhiteLaura MauriPiotr SobieszczkyAlex SmithLaura AseltineRick StoufferAlan HinderliterEric PauleyTyrone WadeDavid ZidarMehdi ShishehborBarry EffronMarco CostaTerence SemenecChanwit RoongsritongPriscilla NelsonBridget NeumannDebbie CohenJay GiriRobin NeubauerThu VoAtul R ChughPei-Hsiu HuangPowell JoseJohn FlackRobert FishmanMichael JonesTodd AdamsChristopher BajzerAnthony MathurAjay JainArmida BalawonOlivier ZongoClare BentDavid BeckettNicki LakemanSarah KennardRichard J D’souzaSarah StattonLindsay WilkesChristine AnningJeremy SayerSudha Ganesh IyerNicholas RobinsonAnnaliza SevillanoMadelaine OcampoRobert GerberMohamad FarisAndrew John MarshallJanet SinclairHayley PepperJustin DaviesNeil ChapmanPaula BurakPaula CarvelliSachin JadhavJane QuinnLars Christian RumpJohannes StegbauerLars SchimmöllerSebastian PotthoffClaudia SchmidSylvia RoederJoachim WeilLukas HaferTolga AgdirliogluTanja KöllnerMichael BöhmSebastian EwenSaarraaken KulenthiranAngelika WachterChristina KochKarl FenglerKarl-Philipp RommelKai TrautmannMartin PetzoldChristian OttAxel SchmidMichael UderUlrike HeinritzKerstin Fröhlich-EndresSabine Genth-ZotzDenise KämpfnerArmin GraweJohannes HöhneBärbel KaesbergerConstantin von Zur MühlenDennis WolfMarkus WelzelGudrun HeinrichsBarbara TrabitzschAntoine CremerHervé TrillaudPanteleimon PapadopoulosFlorent MaireJulie GaudissardMarc SapovalMarine LivrozetAurélien LorthioirLaurence AmarValérie PaquetAtul PathakBenjamin HontonMarianne CottinFrédéric PetitPierre LantelmeConstance BergePierre-Yves CourandFatou LangevinPascal DelsartBenjamin LongereGuillaume LedieuFrançois PontanaCoralie SommevilleFabien BertrandLida FeyzVictor ZeijenArno RuiterElisabeth HuyskenPeter BlankestijnMichiel VoskuilZwaantina RittersmaHelma DolmansA.A. KroonW.H. van ZwamJeannique VrankenClaudia de Haan.Jean RenkinFrédéric MaesChristophe BeauloyeJean-Philippe LengeléDominique HuyberechtsAnne BouvieAdam WitkowskiAndrzej JanuszewiczJacek KądzielaAleksander PrejbisjDagmara HeringDariusz CiecwierzMilosz J JaguszewskiRadoslaw Owczuk
• Organismes : CIC - HEGP Hôpital Européen Georges Pompidou [APHP] CArdiovasculaire Rénal Transplantation nEurovasculaire [Paris] Universität des Saarlandes [Saarbrücken] = Saarland University [Saarbrücken] SUNY Downstate Medical Center University Hospital of Wales University of Exeter Universitätsklinikum Erlangen [Erlangen] Leipzig University / Universität Leipzig Queen Mary University of London Brigham & Women’s Hospital [Boston] Erasmus University Medical Center [Rotterdam] University of Nevada [Reno] Medical University of South Carolina [Charleston] Queen Mary University of London Hôpital Saint-André [Bordeaux] Royal Bournemouth Hospital Université Catholique de Louvain = Catholic University of Louvain Cliniques Universitaires Saint-Luc [Bruxelles] Hôpital Européen Georges Pompidou [APHP] ReCor Medical Inc Columbia University Medical Center Danderyds sjukhus = Danderyd University Hospital University of Vermont [Burlington] Stanford University Argolyn Bioscience, Inc.
• Publié dans JAMA Cardiology le 25/10/2020

---

Résumé : Importance Although early trials of endovascular renal denervation (RDN) for patients with resistant hypertension (RHTN) reported inconsistent results, ultrasound RDN (uRDN) was found to decrease blood pressure (BP) vs sham at 2 months in patients with RHTN taking stable background medications in the Study of the ReCor Medical Paradise System in Clinical Hypertension (RADIANCE-HTN TRIO) trial. Objectives To report the prespecified analysis of the persistence of the BP effects and safety of uRDN vs sham at 6 months in conjunction with escalating antihypertensive medications. Design, Setting, and Participants This randomized, sham-controlled, clinical trial with outcome assessors and patients blinded to treatment assignment, enrolled patients from March 11, 2016, to March 13, 2020. This was an international, multicenter study conducted in the US and Europe. Participants with daytime ambulatory BP of 135/85 mm Hg or higher after 4 weeks of single-pill triple-combination treatment (angiotensin-receptor blocker, calcium channel blocker, and thiazide diuretic) with estimated glomerular filtration rate (eGFR) of 40 mL/min/1.73 m 2 or greater were randomly assigned to uRDN or sham with medications unchanged through 2 months. From 2 to 5 months, if monthly home BP was 135/85 mm Hg or higher, standardized stepped-care antihypertensive treatment starting with aldosterone antagonists was initiated under blinding to treatment assignment. Interventions uRDN vs sham procedure in conjunction with added medications to target BP control. Main Outcomes and Measures Six-month change in medications, change in daytime ambulatory systolic BP, change in home systolic BP adjusted for baseline BP and medications, and safety. Results A total of 65 of 69 participants in the uRDN group and 64 of 67 participants in the sham group (mean [SD] age, 52.4 [8.3] years; 104 male [80.6%]) with a mean (SD) eGFR of 81.5 (22.8) mL/min/1.73 m 2 had 6-month daytime ambulatory BP measurements. Fewer medications were added in the uRDN group (mean [SD], 0.7 [1.0] medications) vs sham (mean [SD], 1.1 [1.1] medications; P = .045) and fewer patients in the uRDN group received aldosterone antagonists at 6 months (26 of 65 [40.0%] vs 39 of 64 [60.9%]; P = .02). Despite less intensive standardized stepped-care antihypertensive treatment, mean (SD) daytime ambulatory BP at 6 months was 138.3 (15.1) mm Hg with uRDN vs 139.0 (14.3) mm Hg with sham (additional decreases of −2.4 [16.6] vs −7.0 [16.7] mm Hg from month 2, respectively), whereas home SBP was lowered to a greater extent with uRDN by 4.3 mm Hg (95% CI, 0.5-8.1 mm Hg; P = .03) in a mixed model adjusting for baseline and number of medications. Adverse events were infrequent and similar between groups. Conclusions and Relevance In this study, in patients with RHTN initially randomly assigned to uRDN or a sham procedure and who had persistent elevation of BP at 2 months after the procedure, standardized stepped-care antihypertensive treatment escalation resulted in similar BP reduction in both groups at 6 months, with fewer additional medications required in the uRDN group. Trial Registration ClinicalTrials.gov Identifier: NCT02649426

---

Fichiers liés : 2022-Azizi-JAMA cardiology.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/12/2022
• Auteurs : Magali ColombatMargot GaspardMylène CamusJessica Dalloux-ChioccioliAudrey DelasElsa PoullotAnissa MoktefiArnaud FrançoisAnne MoreauJean-Bapiste GibierPierre RaynaudAntoine HuartAlexis PiedrafitaJulia GilhodesOlivier LairezGilles GrateauSophie Georgin-LavialleHervé MaisonneuvePhilippe MoreauArnaud JaccardFranck BridouxViolaine Plante-BordeneuveThibaud DamyHervé MalPierre BroussetSophie ValleixOdile Burlet-Schiltz
• Organismes : Institut Universitaire du Cancer de Toulouse - Oncopole Institut Universitaire du Cancer de Toulouse - Oncopole Institut de pharmacologie et de biologie structurale Institut Universitaire du Cancer de Toulouse - Oncopole Institut Universitaire du Cancer de Toulouse - Oncopole CHU Henri Mondor [Créteil] CHU Henri Mondor [Créteil] Institut Mondor de Recherche Biomédicale Service d'Anatomie et Cytologie Pathologique [CHU Rouen] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Institut de Pathologie [CHU Lille] CH Perpignan Département de Néphrologie et Transplantation d'organes [CHU Toulouse] Département de Néphrologie et Transplantation d'organes [CHU Toulouse] Institut des Maladies Métaboliques et Casdiovasculaires Oncopole Claudius Regaud Service Cardiologie [CHU Toulouse] Groupe de recherche clinique Amylose AA Sorbonne Université Groupe de recherche clinique Amylose AA Sorbonne Université CHU Tenon [AP-HP] Groupe de recherche clinique Amylose AA Sorbonne Université Groupe de recherche clinique Amylose AA Sorbonne Université CHU Tenon [AP-HP] Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon Centre Hospitalier Universitaire de Nantes = Nantes University Hospital CHU Limoges Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Institut Mondor de Recherche Biomédicale Département de neurosciences CHU Henri Mondor [Créteil] AP-HP - Hôpital Bichat - Claude Bernard [Paris] Institut Universitaire du Cancer de Toulouse - Oncopole AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris] Centre de Recherche des Cordeliers Institut de pharmacologie et de biologie structurale
• Publié dans Haematologica le 30/10/2020

---

Fichiers liés : 1072983.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/12/2022
• Auteurs : Béninwendé Leticia Delphine SakanaAnaïs MennecierPaulin FaoSouleymane TassembedoJean-Pierre MolesDramane KaniaAjani Ousmane TaofikiFranck Edgar KadebaIbrahima DialloSabrina Eymard-DuvernayMorgana D’ottaviNicolas MedaBeatriz MosqueiraPhilippe van de PerreNicolas Nagot
• Organismes : Centre Muraz [Bobo-Dioulasso, Burkina Faso] Pathogenesis and Control of Chronic and Emerging Infections Centre Muraz [Bobo-Dioulasso, Burkina Faso] Centre Muraz [Bobo-Dioulasso, Burkina Faso] Pathogenesis and Control of Chronic and Emerging Infections Centre Muraz [Bobo-Dioulasso, Burkina Faso] Centre Muraz [Bobo-Dioulasso, Burkina Faso] Centre Muraz [Bobo-Dioulasso, Burkina Faso] Centre Muraz [Bobo-Dioulasso, Burkina Faso] Inserm Occitanie Méditerranée (Montpellier) Pathogenesis and Control of Chronic and Emerging Infections Institut National de Santé Publique [Ouagadougou] Pathogenesis and Control of Chronic and Emerging Infections Pathogenesis and Control of Chronic and Emerging Infections Pathogenesis and Control of Chronic and Emerging Infections
• Publié dans Bulletin of the World Health Organization le 22/10/2020

---

Résumé : Objective: to evaluate the performance of the cascade of activities for prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) at the second immunization visit in Burkina Faso. Methods: in a cross-sectional study, we recruited mothers attending the second immunization visit for their infant in 20 health centres of Bobo-Dioulasso city, Burkina Faso over 12 months (2019–2020). We administered a short questionnaire to 14 176 mothers and performed HIV serological tests on mothers who had not been tested in the last 3 months. All mothers were asked about their attendance for antenatal care and HIV rapid testing. HIV-infected mothers were also asked about the timing of their HIV diagnosis, antiretroviral therapy, pre-exposure prophylaxis initiation at birth and infant diagnosis of HIV. Findings: of 14 136 respondents, 13 738 (97.2%) had at least one HIV serological test in their lifetime. Of 13 078 mothers who were never tested or were HIV-negative, 12 454 (95.2%) were tested during or after their last pregnancy. Among HIV-infected mothers already aware of their status, 110/111 (99.1%) women were on antiretroviral therapy. Among HIV-exposed infants, 84/101 (83.2%) babies received 6 weeks of antiretroviral prophylaxis at birth and 58/110 (52.7%) had a blood sample collected for early infant diagnosis. Only two mothers received their child’s test results at the time of the second immunization visit. Four mothers were newly diagnosed as HIV-positive during the study. Conclusion: collecting data at the second immunization visit, a visit rarely missed by mothers, could be useful for identifying gaps in the PMTCT cascade in settings where mothers are difficult to reach, such as in low-income countries with intermediate or low HIV prevalence.

---

Fichiers liés : BLT.22.288522.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/12/2022
• Auteurs : David MalkaNicolas GirardDavid M SmadjaChristine ChevreauStéphane CulineAnne LesurRoman RouzierFrançois RozetJean-Philippe SpanoJean-Yves Blay
• Organismes : Dynamique des cellules tumorales Epidémiologie, Systèmes d'Information, Modélisation
• Publié dans Bulletin du Cancer le 01/11/2020

---

Fichiers liés : [Prophylaxis and management of cancer-associated thrombosis Practical issues about anticoagulant use]..pdf

---

Source